Skip to main content
  • Saranas® Expands Intellectual Property with Key Patent Integrating Bleed Monitoring and Vascular Access Closure Device

    HOUSTON, TX, February 23, 2022 – Saranas, a company focused on improving patient outcomes through early detection and monitoring of internal bleeding complications, announced today that the U.S. Department of Commerce’s United States Patent and Trademark Office (USPTO) has issued them Patent No. 11,224,414. Titled “Access Closure with Bleed Monitoring,” this key patent allows for embedding a vascular access closure device with the company’s proprietary bleed monitoring technology. Saranas’ Early Bird Bleed Monitoring System® is the first and only FDA-approved device for real-time detection and monitoring of endovascular bleed complications.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details